Effects of Biologics on Immune Cells in Severe Asthma
Author Information
Author(s): Park Kyungtaek, Lee Ji-Hyang, Shin Eunsoon, Jang Hye Yoon, Song Woo-Jung, Kwon Hyouk-Soo, Cho Yoo Sook, Lee Jong Eun, Adcock Ian, Chung Kian Fan, Lee Jeong Seok, Won Sungho, Kim Tae-Bum
Primary Institution: Institute of Health and Environment, Seoul National University
Hypothesis
Can single-cell RNA sequencing reveal the transcriptional changes in circulating immune cells from patients with severe asthma induced by biologics?
Conclusion
Biologics used in severe asthma treatment reduce inflammation by altering specific immune cell pathways.
Supporting Evidence
- Biologics reduced IL1B+ classical monocytes and increased S100A+ classical monocytes.
- Significant downregulation of the NF-κB pathway was observed across immune cells.
- Transcriptional changes in PBMCs occurred at least one month after the initiation of treatment with biologics.
- Patients treated with dupilumab showed different cell-cell interactions compared to those treated with mepolizumab or reslizumab.
Takeaway
Researchers studied how treatments for severe asthma change the genes in immune cells. They found that these treatments help by reducing inflammation.
Methodology
Single-cell RNA sequencing of peripheral blood mononuclear cells from patients before and after treatment with biologics.
Potential Biases
Participants exhibited good responses to treatment, limiting the ability to identify predictive signatures for treatment response.
Limitations
The study had a small sample size and did not include granulocytes, which could also play an important role in severe asthma.
Participant Demographics
Eight patients with severe eosinophilic asthma, treated with different biologics.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website